Telix Pharmaceuticals is trading at A$12.63, down 4.25%, after a report said its October 21 third-quarter update spooked investors; though no new company announcement was identified to explain the October 26 move.
- The update showed revenue down 1% sequentially, while Precision Medicine revenue was flat quarter over quarter; year-over-year revenue grew and full-year guidance was reaffirmed.
- Several sessions of declines followed. Reported volume on October 23 was 3,151,131 shares.